Case report

Post-artesunate delayed hemolysis after treatment of malaria with intravenous artesunate: A case study

Abigail Foster
Internal Medicine of Tampa Bay 508 S Habana Ave Ste 335, Tampa, FL 33609, USA

A R T I C L E   I N F O

Article history:
Received 18 November 2021
Received in revised form 20 January 2022
Accepted 22 January 2022

Keywords:
Malaria
Anemia
Hemolysis
Artesunate
Infectious disease
Parasite

A B S T R A C T

Delayed hemolysis is an uncommon reaction to intravenous artesunate for the treatment of severe malaria. We report a case of a patient who developed severe malaria after initial improper treatment, thus requiring IV artesunate therapy. Delayed hemolytic anemia then occurred and was monitored for weeks after completion of treatment.

Introduction

Malaria is a vector-borne infectious parasite that is transmitted through mosquitoes. It is a very prevalent disease globally, usually in areas of the world that are sub-tropical, typically in Africa and South Asia. According to the World Health Organization (WHO), there are about 2,000 cases of malaria reported in the United States annually, predominantly reported from travelers returning from these regions [1]. There are different treatment options for malaria, which are determined based on different factors such as the infecting species, the clinical status of the patient, and any previous use of antimalarials [2]. Prophylactics can also be used to prevent the onset of malarial infection. Common drugs used to treat and prevent malaria are doxycycline, chloroquine phosphate, quinine-based drugs, and artemisinin-based drugs [3]. Severe malaria is identified by different clinical manifestations which include but are not limited to parasite density > 5%, hemoglobin < 7 g/dL, acute kidney injury, jaundice, and splenomegaly [4]. In the case of severe malaria, patients should be aggressively treated with intravenous artesunate. While it is not yet licensed in the United States, it is the first line defense for severe malaria in other parts of the world such as Africa and Asia [5].

In rare cases, delayed hemolytic anemia can occur following treatment with artesunate. If post-artemisinin delayed hemolytic anemia (PADH) occurs, patients need routine lab work done for four weeks following to monitor hemoglobin, reticulocyte count, haptoglobin, lactate dehydrogenase, and total bilirubin [2]. PADH occurs due to the delayed clearance of erythrocytes after the parasitic infection has been eradicated [6]. It is important to be aware of the incidence of PADH because it occurs after the parasites have been cleared and malarial symptoms have alleviated. It needs to be monitored in case the patient requires blood transfusions. Intravenous artesunate is the first-line defense against severe malaria throughout the world, and PADH is a rare occurrence. The goal of this case report is to track the symptoms and progress of a patient who developed hemolytic anemia following IV artesunate treatment for severe malaria.

Case report

A 25-year-old female presented to the emergency department after returning from Ghana 2 days prior. No prophylactics were taken for the visit to Africa, where malaria is endemic. Previously, the patient had worked for the Peace Corps and received prophylaxis automatically. She was febrile (104 degrees Fahrenheit), suffering from diarrhea and hypotension. Her blood smear came back as positive for malaria, suspected to be Plasmodium falciparum. Labs showed normal hemoglobin (15.3 g/dL) and high lactate dehydrogenase (LDH 275 IU/L). After being discharged with doxycycline for treatment of malaria, the patient returned to the emergency department 5 days later. She reported worsening symptoms and the inability to tolerate oral medications. Her symptoms were chills, nausea and vomiting, dizziness, and generalized malaise. She was then admitted to the intensive care unit and diagnosed with septic malaria and influenza. Labs revealed acute kidney injury with creatine of 2.5, BUN of 58, and lactate 3.2. After being unable to transfer to hospitals with artesunate for treatment, the hospital acquired intravenous...
artesunate from the Center for Disease Control (CDC). When the patient was first admitted to the hospital, hemoglobin was found to be 13.6 g/dL. Lab tests were repeated after the patient received intravenous artesunate and for several days following until discharge. After treatment with IV artesunate, the patient was found to be thrombocytopenic (platelets of 12,000) and anemic (Hgb 7.9 g/dL). The patient received several units of blood; however, she is unaware exactly how many.

On the day of discharge, further laboratory tests were consistent with hemolytic anemia: reticulocyte count 6.2%, LDH 512 U/L, and 29.1% Hematocrit.

After hospital discharge, she came into our care for further monitoring. The patient followed up with weekly labs for the course of 4 weeks. The only abnormalities present at final testing were elevated reticulocyte count and hemoglobin, as well as a decrease of haptoglobin and lactate dehydrogenate. These values indicate that our patient experienced delayed hemolytic anemia following intravenous artesunate treatment.

| Date                   | Hematocrit (%) | LDH (U/L) | Reticulocyte Count (%) | Hemoglobin (g/dL) |
|------------------------|----------------|-----------|------------------------|-------------------|
| initial presentation   | 44.6           | 275       | 0.8                    | 15.3              |
| second presentation    | 38.9           | 737       | 0.6                    | 13.6              |
| hospital day 1         | 22.1           | 541       | 0.6                    | 10.2              |
| hospital day 2         | 20.7           | 545       | 0.4                    | 7.9               |
| hospital day 3         | 22.9           | 515       | 6.2                    | 7.3               |
| hospital day 4         | 29.1           | 512       | 5.86                   | 8.4               |
| post-discharge week 1  | 28.9           | 368       | 4.86                   | 9.6               |
| post-discharge week 2  | 28.9           | 258       | 4.4                    | 10                |
| post-discharge week 3  | 29.9           | 217       | 3.19                   | 10.1              |
| post-discharge week 4  | 33.3           | 192       | 2.45                   | 11.4              |

Discussion

The case above represents an inadequate initial treatment of malaria, leading to the development of severe malarial symptoms. This onset of severe symptoms required the patient to be treated with intravenous artesunate instead of other quinine therapies because it shows a greater reduction in mortality [7]. It is important to treat malaria in a timely manner so that septic malaria does not occur.

When our patient first presented to the hospital, she was not admitted for malaria, and was released from care prematurely with doxycycline for treatment of her symptoms. After the patient was sent home, it was then confirmed by the hospital that her blood smear was positive for malaria. While doxycycline is a defense against malaria in some cases, it was incorrectly used in this situation. Doxycycline is often used as a prophylactic treatment for malaria, rather than therapeutic [8]. Studies show that as a protective measure, doxycycline is highly effective against preventing several types of malarial infection. When using it post infection, doxycycline must be used in conjunction with a fast-acting schizonticide [8]. In the case of our patient, she initially was treated solely with doxycycline, thus allowing the parasites to propagate. After she was sent home, she was unable to tolerate the medications orally. Her condition worsened rapidly, she then developed acute kidney injury, sepsis, and weakness. It is important to either take prophylactic medications when traveling to areas where malaria is endemic or receive adequate treatment immediately upon diagnosis of malaria. As noted by the CDC, febrile patients travelling from areas where malaria is endemic should be properly diagnosed and treated for malarial parasitic infection immediately and monitored for response.

Since our patient was diagnosed with severe malaria, she then had to receive intravenous artesunate to combat the high level of blood parasites. Intravenous artesunate is extremely effective in the case of severe malaria due to its rapid and total clearance of parasites from the blood, and the ease of administration [9]. Although it is safe to use, in patients with high parasitic load, delayed hemolysis is a slightly common reaction [6, 10]. According to a nonrandomized study of travelers with severe malaria, delayed hemolysis occurred in 20–25% of patients treated with intravenous artesunate. This reaction to artesunate treatment needs to be noted so that post-treatment care can be managed accordingly. Hemolysis occurs from
Artesunate use due to the mechanism of action for eradicating the parasite from the erythrocytes. Artesunate is used to induce pitting, a process in the spleen which expels the parasite from the erythrocyte [6]. After eradication, the erythrocytes seal themselves rather than lyse, then re-entering circulation with a reduced lifespan [6]. PADH is consistent with high lactate dehydrogenase and low serum haptoglobin, as seen in our patient. Additionally, the level of parasitemia is believed to increase the level of hemolysis that occurs [5]. These markers prove recent RBC destruction in the body.

Delayed hemolysis following intravenous artemesunate therapy is relatively uncommon to be reported in the United States. In 2010, the CDC only had reports of 176 cases of severe malaria, and 39 of those patients had been treated with intravenous artemesunate. Of those 39 patients, 19 cases of post artemesunate delayed hemolysis were found [11]. The CDC then updated that report in 2014, stating that 20 new cases of PADH had been reported through literature review and retrospective case studies [12]. Although it is not often reported, it is important to note that if it does occur, patients can be properly treated and monitored. Proper monitoring includes CBC values, LDH, and haptoglobin taken weekly for 4–6 weeks after the completion of artemesunate therapy for severe malaria.

Conclusion

The evidence presented above links the incidence of delayed hemolytic anemia after treatment with intravenous artemesunate. After receiving the treatment, the patient's clinical status improved rapidly as malarial parasites were cleared, but complications of post-treatment hemolysis occurred. It is important to gather this evidence so that hemolytic anemia can be monitored if the patient has been diagnosed and treated for severe malaria with intravenous artemesunate.

CRediT authorship contribution statement

Abigail Foster: Conceptualization, Methodology, Investigation, Writing – original draft. Preeti Kallu: Supervision, Writing – review & editing.

Ethical approval

No experiments were performed and patient consent was given.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Funding

There is nothing to declare.

Conflicts of interest

There is nothing to declare.

References

[1] Centers for Disease Control and Prevention [Internet]. CDC. [Accessed 28 September 2021]. About Malaria. Available from: https://www.cdc.gov/malaria/about/index.html.
[2] Centers for Disease Control and Prevention [Internet]. CDC. [Accessed 28 September 2021]. Diagnosis and Treatment. Available from: https://www.cdc.gov/malaria/diagnosis-treatment/index.html.
[3] Mayo Foundation for Medical Education and Research [Internet]. Mayo Clinic. 2021. [Accessed 26 October 2021]. Malaria. Available from: https://www.mayoclinic.org/diseases-conditions/malaria/diagnosis-treatment/drc-2035190.
[4] Centers for Disease Control and Prevention [Internet]. CDC. [Accessed 26 October 2021]. Artesunate. Available from: https://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html.
[5] Lahoud JS, Lahoud OB, Lin YS, Ghitan M, Chapnick EK, Solomon WB, et al. Artesunate-related fever and delayed hemolysis in a returning traveler. IDCases 2015;2(2):63–5. https://doi.org/10.1016/j.idcr.2015.04.002
[6] Jauréguiberry S, Ndour PA, Roussel C, Ader F, Saffouk I, Nguyen M, et al. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2015;124(2):167–75. https://doi.org/10.1182/blood-2014-05-55953.
[7] Sinclair D, Donegan S, Isba R, Laloo D. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;2012(6):CD005967.
[8] Tan KR, Magill AJ, Arguin PM, Parise ME. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg 2011;84(4):517–31. https://doi.org/10.4269/ajtmh.2011.10-0395.
[9] Centers for Disease Control and Prevention [Internet]. Intravenous artemesunate for severe malaria in travelers. Eur Emerg Infect Dis J CDC 2015;15(5). https://wwwnc.cdc.gov/eid/article/17/5/15-0295_article.
[10] Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard G-D, Cramer JP. Post-treatment haemolysis in severe imported malaria after intravenous artemesunate: Case report of three patients with Hyperparasitaemia. Malar J 2012;11(1):169. https://doi.org/10.1186/1475-2875-11-169.
[11] Centers for Disease Control and Prevention [Internet]. CDC. [Accessed 12 January 2022]. Published reports of delayed hemolytic anemia after treatment with artemesunate for severe malaria - worldwide, 2010-2012. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a2.htm.
[12] Centers for Disease Control and Prevention [Internet]. CDC. [Accessed 11 2021]. Update on cases of delayed hemolysis after parenteral artemesunate therapy for malaria - united states, 2008 and 2013. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6334a3.htm.